Mark DeMario

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski et al. · Cell · 2020 · 743 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Anthony W. Tolcher, Wells A. Messersmith, Stanislaw M. Mikulski et al. · Journal of Clinical Oncology · 2012 · 279 citations · Full text

Medicine, Oncology, Pharmacology +17

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh et al. · Cancer Cell · 2022 · 222 citations

Medicine, Immunology, Oncology +16

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati et al. · British Journal of Cancer · 2020 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Xuefeng Yin, Leopoldo Luistro, Hua Zhong et al. · Clinical Cancer Research · 2013 · 48 citations · Full text

Medicine, Immunology, Pharmacology +17